BUZZ-Dexcom rises after forecasting 2025 revenue in-line with estimates

** Medical device maker Dexcom's DXCM.O shares rise 5.2% to $81.52 premarket

** Co forecasts 2025 revenue of $4.60 bln, in-line with analysts' estimates of $4.61 bln as per data compiled by LSEG

** Co in August launched its over-the-counter device Stelo in the U.S. for adults aged 18 and older who do not use insulin, making it the first continuous glucose monitor available for over-the-counter sales

** Co says the forecast was driven in part by "increasing CGM access and awareness for people with diabetes, the continued rollout of Stelo"

** Reports preliminary Q4 revenue of at least $1.11 bln vs analysts' estimates of $1.10 bln

** Stock had fallen 37.3% in 2024

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))